TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life
TrYbe® is an Fc-free therapeutic antibody format, capable of engaging up to three targets simultaneously, with long in vivo half-life conferred by albumin binding. This format is shown by small-angle X-ray scattering to be conformationally flexible with favorable ‘reach’ properties. We demonstrate t...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2022.2160229 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849468403950026752 |
|---|---|
| author | Emma Davé Oliver Durrant Neha Dhami Joanne Compson Janice Broadbridge Sophie Archer Asher Maroof Kevin Whale Karelle Menochet Pierre Bonnaillie Emily Barry Gavin Wild Claude Peerboom Pallavi Bhatta Mark Ellis Matthew Hinchliffe David P. Humphreys Sam P. Heywood |
| author_facet | Emma Davé Oliver Durrant Neha Dhami Joanne Compson Janice Broadbridge Sophie Archer Asher Maroof Kevin Whale Karelle Menochet Pierre Bonnaillie Emily Barry Gavin Wild Claude Peerboom Pallavi Bhatta Mark Ellis Matthew Hinchliffe David P. Humphreys Sam P. Heywood |
| author_sort | Emma Davé |
| collection | DOAJ |
| description | TrYbe® is an Fc-free therapeutic antibody format, capable of engaging up to three targets simultaneously, with long in vivo half-life conferred by albumin binding. This format is shown by small-angle X-ray scattering to be conformationally flexible with favorable ‘reach’ properties. We demonstrate the format’s broad functionality by co-targeting of soluble and cell surface antigens. The benefit of monovalent target binding is illustrated by the lack of formation of large immune complexes when co-targeting multivalent antigens. TrYbes® are manufactured using standard mammalian cell culture and protein A affinity capture processes. TrYbes® have been formulated at high concentrations and have favorable drug-like properties, including stability, solubility, and low viscosity. The unique functionality and inherent developability of the TrYbe® makes it a promising multi-specific antibody fragment format for antibody therapy. |
| format | Article |
| id | doaj-art-da5a5f25917d459295f40b2ca83010e7 |
| institution | Kabale University |
| issn | 1942-0862 1942-0870 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | mAbs |
| spelling | doaj-art-da5a5f25917d459295f40b2ca83010e72025-08-20T03:25:53ZengTaylor & Francis GroupmAbs1942-08621942-08702023-12-0115110.1080/19420862.2022.2160229TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-lifeEmma Davé0Oliver Durrant1Neha Dhami2Joanne Compson3Janice Broadbridge4Sophie Archer5Asher Maroof6Kevin Whale7Karelle Menochet8Pierre Bonnaillie9Emily Barry10Gavin Wild11Claude Peerboom12Pallavi Bhatta13Mark Ellis14Matthew Hinchliffe15David P. Humphreys16Sam P. Heywood17Early Solutions, UCB Biopharma UK, Slough, UKEarly Solutions, UCB Biopharma UK, Slough, UKEarly Solutions, UCB Biopharma UK, Slough, UKEarly Solutions, UCB Biopharma UK, Slough, UKEarly Solutions, UCB Biopharma UK, Slough, UKEarly Solutions, UCB Biopharma UK, Slough, UKEarly Solutions, UCB Biopharma UK, Slough, UKEarly Solutions, UCB Biopharma UK, Slough, UKEarly Solutions, UCB Biopharma UK, Slough, UKEarly Solutions, UCB Biopharma UK, Slough, UKEarly Solutions, UCB Biopharma UK, Slough, UKPV Supply and Technology Solutions, UCB Biopharma UK, Slough, UKPV Supply and Technology Solutions, UCB Biopharma SRL, Braine-l'Alleud, Belgium, EUEarly Solutions, UCB Biopharma UK, Slough, UKEarly Solutions, UCB Biopharma UK, Slough, UKEarly Solutions, UCB Biopharma UK, Slough, UKEarly Solutions, UCB Biopharma UK, Slough, UKEarly Solutions, UCB Biopharma UK, Slough, UKTrYbe® is an Fc-free therapeutic antibody format, capable of engaging up to three targets simultaneously, with long in vivo half-life conferred by albumin binding. This format is shown by small-angle X-ray scattering to be conformationally flexible with favorable ‘reach’ properties. We demonstrate the format’s broad functionality by co-targeting of soluble and cell surface antigens. The benefit of monovalent target binding is illustrated by the lack of formation of large immune complexes when co-targeting multivalent antigens. TrYbes® are manufactured using standard mammalian cell culture and protein A affinity capture processes. TrYbes® have been formulated at high concentrations and have favorable drug-like properties, including stability, solubility, and low viscosity. The unique functionality and inherent developability of the TrYbe® makes it a promising multi-specific antibody fragment format for antibody therapy.https://www.tandfonline.com/doi/10.1080/19420862.2022.2160229TrYbe®multi-specificmonovalentFc-freetargetingmultivalent antigen |
| spellingShingle | Emma Davé Oliver Durrant Neha Dhami Joanne Compson Janice Broadbridge Sophie Archer Asher Maroof Kevin Whale Karelle Menochet Pierre Bonnaillie Emily Barry Gavin Wild Claude Peerboom Pallavi Bhatta Mark Ellis Matthew Hinchliffe David P. Humphreys Sam P. Heywood TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life mAbs TrYbe® multi-specific monovalent Fc-free targeting multivalent antigen |
| title | TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life |
| title_full | TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life |
| title_fullStr | TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life |
| title_full_unstemmed | TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life |
| title_short | TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life |
| title_sort | trybe r an fc free antibody format with three monovalent targeting arms engineered for long in vivo half life |
| topic | TrYbe® multi-specific monovalent Fc-free targeting multivalent antigen |
| url | https://www.tandfonline.com/doi/10.1080/19420862.2022.2160229 |
| work_keys_str_mv | AT emmadave trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT oliverdurrant trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT nehadhami trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT joannecompson trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT janicebroadbridge trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT sophiearcher trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT ashermaroof trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT kevinwhale trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT karellemenochet trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT pierrebonnaillie trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT emilybarry trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT gavinwild trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT claudepeerboom trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT pallavibhatta trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT markellis trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT matthewhinchliffe trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT davidphumphreys trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife AT sampheywood trybeanfcfreeantibodyformatwiththreemonovalenttargetingarmsengineeredforlonginvivohalflife |